Highlights Novartis AG Swiss Exchange

Equities

NOVNEE

CH0038459415

Market Closed - Swiss Exchange Other stock markets 09:00:41 31/05/2024 pm IST			5-day change	1st Jan Change
93.06 ^CHF	+1.67%		+1.43%	+10.04%

02:00pm	Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes	RE
31/05	NOVARTIS AG : UBS reiterates its Buy rating	ZD

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes	05:30pm	RE
European Equities Close Higher in Friday Trading; Flash Euro Area Inflation Rises More Than Expected	31/05	MT
Swiss Market Index in the Green Amid US Rate Cut Optimism	31/05	MT
Novartis Says Late-Stage Scemblix Trial Meets Primary Endpoints	31/05	MT
Novartis Says New Data Show Long-term Efficacy, Safety of Potential Urticaria Therapy	31/05	MT
Novartis Blood Cancer Drug Scemblix Meets Main Goals of Late-stage Study	31/05	MT
Novartis: positive trial results in chronic myeloid leukemia	31/05	CF
Novartis Blood Cancer Drug Scemblix Meets Main Goals of Late-stage Study	31/05	MT
Novartis: efficacy of remibrutinib in urticaria -USC	31/05	CF
Novartis' Chronic Spontaneous Urticaria Treatment Shows Long-term Efficacy in Late-stage Trial Data	31/05	MT
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria	31/05	DJ
Alembic Pharmaceuticals Gets US FDA Final Nod for Sacubitril and Valsartan Tablets	30/05	MT
Novartis: positive phase III results in C3G	27/05	CF
Novartis: presented results for kidney disease	27/05	CF
Novartis Presents Favorable Study Results for Rare Kidney Disease Medication Fabhalta	27/05	MT
Novartis Reports Positive Results from Phase 3 Study of Investigational Chronic Kidney Disease Drug	27/05	MT
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio	25/05	DJ
Novartis Presents Results from a Pre-Specified Interim Analysis of the Phase III Align Study	25/05	CI
Novartis AG Presents Latest Phase III Fabhalta®? Data in C3 Glomerulopathy	25/05	CI
Novartis' Cosentyx Receives Canadian Approval for Hidradenitis Suppurativa Treatment	23/05	MT